1. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome. (April 2023) Authors: Begg, Malcolm; Amour, Augustin; Jarvis, Emily; Tang, Teresa; Franco, Sara Santos; Want, Andrew; Beerahee, Misba; Fernando, Disala; Karkera, Yakshitha; Sander, Clare; Southworth, Thomas; Singh, Dave; Clark, Jonathan; Nejentsev, Sergey; Okkenhaug, Klaus; Condliffe, Alison; Chandra, Anita; Cahn, Ant... Journal: Pulmonary pharmacology & therapeutics Issue: Volume 79(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗